公开(公告)号：US20250051365A1

公开(公告)日：2025-02-13

申请号：US18892208

申请日：2024-09-20

Applicant: Quanta Therapeutics, Inc.

Inventor： Hong LIN ,  Juan LUENGO ,  Audrey HOSPITAL ,  Jin ZENG ,  Pei GAN

IPC: C07D519/00 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61K31/675 ,  C07D487/04 ,  C07D487/08 ,  C07D495/10 ,  C07D495/20 ,  C07F9/6561

Abstract: Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (I-A), (I-B), (I-C), (I-C*), (I-D), (I-E), (I-F), (I-G), (I-H), (I-I), (I-J), or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any one thereof. The compounds provided herein are useful for modulating KRAS GD12 and/or other G12 mutants.

公开(公告)号：US12202838B2

公开(公告)日：2025-01-21

申请号：US17275985

申请日：2019-11-08

Applicant: LG CHEM, LTD.

Inventor： Dong Uk Heo ,  Sung Kil Hong ,  Jungoh Huh ,  Yongbum Cha ,  Miyeon Han ,  Jae Tak Lee ,  Junghoon Yang

IPC: C07D493/10 ,  C07D495/10 ,  C07D498/10 ,  H10K85/60 ,  H10K50/11 ,  H10K101/10 ,  H10K101/30 ,  H10K101/40

Abstract: A heterocyclic compound represented by Chemical Formula 1 and an organic light emitting device including the same, and the heterocyclic compound which is used as a material of an organic material layer of the organic light emitting device and provides improved efficiency, low driving voltage and improved lifetime characteristics of the organic light emitting device.

公开(公告)号：US12172995B2

公开(公告)日：2024-12-24

申请号：US17287612

申请日：2019-10-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John L. Gilmore ,  Shoshana L. Posy ,  Alaric J. Dyckman

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/5377 ,  A61P37/00 ,  C07D401/14 ,  C07D491/107 ,  C07D495/10 ,  C07D519/00

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X is CR1 or N; and G, A, R1; and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US12098145B2

公开(公告)日：2024-09-24

申请号：US18543599

申请日：2023-12-18

Applicant: Libra Therapeutics, Inc.

Inventor： James Guy Breitenbucher ,  Maria Pia Catalani ,  Ali Munaim Yousif

IPC: C07D263/48 ,  A61K31/422 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D491/048 ,  C07D491/056 ,  C07D491/08 ,  C07D491/107 ,  C07D495/10 ,  C07D498/04

CPC classification number: C07D413/04 ,  C07D263/48 ,  C07D413/12 ,  C07D413/14 ,  C07D491/048 ,  C07D491/056 ,  C07D491/08 ,  C07D491/107 ,  C07D495/10 ,  C07D498/04

Abstract: Described herein are oxazole TRPML1 agonists and pharmaceutical compositions comprising said agonists. The subject compounds and compositions are useful for the treatment of TRPML1-mediated disorders or diseases.

公开(公告)号：US12084457B2

公开(公告)日：2024-09-10

申请号：US17539715

申请日：2021-12-01

Applicant: UNION therapeutics A/S

Inventor： Allan Carsten Dahl ,  Johan Eriksson Bajtner ,  Esben Paul Krogh Olsen ,  Bjørn Metzler

IPC: C07D495/10 ,  B01J21/16

CPC classification number: C07D495/10 ,  B01J21/16 ,  C07B2200/13

Abstract: The present invention relates to novel methods for the preparation of 1,3-benzo-dioxole heterocyclic compounds. The compounds are useful as PDE4 inhibitors.

公开(公告)号：US20240245681A1

公开(公告)日：2024-07-25

申请号：US18591965

申请日：2024-02-29

Applicant: Jacobo Pharmaceuticats Co., Ltd.

Inventor： Huifeng Han ,  Panliang Gao ,  Cunbo Ma ,  Di Kang

IPC: A61K31/497 ,  A61K31/438 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D417/04 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D495/10 ,  C07D513/04 ,  C07D513/10 ,  C07D519/00

CPC classification number: A61K31/497 ,  A61K31/438 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D417/04 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D495/10 ,  C07D513/04 ,  C07D513/10 ,  C07D519/00 ,  C07B2200/05

Abstract: This invention provides a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention provides a pharmaceutical composition comprising the said compound.

公开(公告)号：US20240199581A1

公开(公告)日：2024-06-20

申请号：US18534395

申请日：2023-12-08

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveshuk ,  Katrina L. Jackson ,  Yanke Liang ,  Robert T. Yu ,  Martin Duplessis ,  Mark E. Fitzgerald ,  Victoria Garza ,  Andrew Charles Good ,  Morgan Welzel O'Shea ,  Gesine Kerstin Veits ,  Cosimo Dolente ,  David Stephen Hewings ,  Daniel Hunziker ,  Daniela Krummenacher ,  Piergiorgio Franceso Tommaso Pettazzoni ,  Juergen Wichmann

IPC: C07D401/14 ,  A61P35/00 ,  C07D405/14 ,  C07D471/10 ,  C07D491/107 ,  C07D495/10

CPC classification number: C07D401/14 ,  A61P35/00 ,  C07D405/14 ,  C07D471/10 ,  C07D491/107 ,  C07D495/10

Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

公开(公告)号：US11937502B2

公开(公告)日：2024-03-19

申请号：US15098258

申请日：2016-04-13

Applicant: Samsung Display Co., Ltd. ,  Research & Business Foundation SUNGKYUNKWAN UNIVERSITY

Inventor： Sung-Wook Kim ,  Myeong-Suk Kim ,  Hwan-Hee Cho ,  Sam-Il Kho ,  Seung-Soo Yoon ,  Changwoong Chu

IPC: H01L51/54 ,  H10K85/60 ,  C09K11/06 ,  C09K11/02 ,  C07D495/10 ,  C07D491/107 ,  H10K50/11

CPC classification number: H10K85/657 ,  C07D491/107 ,  C07D495/10 ,  C09K11/025 ,  C09K11/06 ,  H10K85/626 ,  H10K85/6574 ,  H10K85/6576 ,  C09K2211/1007 ,  C09K2211/1014 ,  H10K50/11

Abstract: A condensed cyclic compound and an organic light-emitting device including the condensed cyclic compound are provided. The condensed cyclic compound is represented by Formula 1. The A3 ring of Formula 1 is a group represented by Formula 2A or a group represented by Formula 2B. The organic light-emitting device includes: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode and including an emission layer, the organic layer including at least one of the condensed cyclic compound represented by Formula 1.

公开(公告)号：US20240083853A1

公开(公告)日：2024-03-14

申请号：US18247119

申请日：2021-09-29

Applicant: FL2022-001, Inc.

Inventor： Steven P. Govek ,  Andiliy G. Lai ,  Andrew R. Hudson ,  Nicholas D. Smith ,  Karensa L. Fasanya

IPC: C07D231/56 ,  C07D401/10 ,  C07D403/04 ,  C07D471/04 ,  C07D249/18 ,  C07D235/26 ,  C07D491/107 ,  C07D413/10 ,  C07D403/10 ,  C07D487/08 ,  C07D401/14 ,  C07D401/12 ,  C07D417/10 ,  C07D495/10

CPC classification number: C07D231/56 ,  C07D401/10 ,  C07D403/04 ,  C07D471/04 ,  C07D249/18 ,  C07D235/26 ,  C07D491/107 ,  C07D413/10 ,  C07D403/10 ,  C07D487/08 ,  C07D401/14 ,  C07D401/12 ,  C07D417/10 ,  C07D495/10

Abstract: Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.

公开(公告)号：US11919839B2

公开(公告)日：2024-03-05

申请号：US17238529

申请日：2021-04-23

Applicant: Valo Health, Inc.

Inventor： Kenneth W. Bair ,  Nicholas Barczak ,  Bingsong Han ,  David R. Lancia, Jr. ,  Cuixian Liu ,  Matthew W. Martin ,  Pui Yee Ng ,  Aleksandra Rudnitskaya ,  Jennifer R. Thomason ,  Mary-Margaret Zablocki ,  Xiaozhang Zheng

IPC: C07C259/06 ,  A61K31/185 ,  A61K31/277 ,  A61K31/397 ,  A61K31/4035 ,  A61K31/407 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/435 ,  A61K31/438 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/451 ,  A61K31/495 ,  A61K31/5377 ,  C07D207/10 ,  C07D207/267 ,  C07D209/08 ,  C07D209/42 ,  C07D209/44 ,  C07D209/46 ,  C07D211/16 ,  C07D211/58 ,  C07D213/56 ,  C07D213/65 ,  C07D213/75 ,  C07D213/81 ,  C07D215/12 ,  C07D221/20 ,  C07D231/14 ,  C07D231/18 ,  C07D233/36 ,  C07D233/38 ,  C07D233/68 ,  C07D235/14 ,  C07D235/30 ,  C07D239/20 ,  C07D239/22 ,  C07D241/08 ,  C07D241/12 ,  C07D249/18 ,  C07D257/04 ,  C07D261/18 ,  C07D277/56 ,  C07D295/155 ,  C07D295/192 ,  C07D307/68 ,  C07D317/68 ,  C07D333/70 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/10 ,  C07D493/08 ,  C07D495/10 ,  C07D498/04 ,  C07D513/10

CPC classification number: C07C259/06 ,  A61K31/185 ,  A61K31/277 ,  A61K31/397 ,  A61K31/4035 ,  A61K31/407 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/435 ,  A61K31/438 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/451 ,  A61K31/495 ,  A61K31/5377 ,  C07D207/10 ,  C07D207/267 ,  C07D209/08 ,  C07D209/42 ,  C07D209/44 ,  C07D209/46 ,  C07D211/16 ,  C07D211/58 ,  C07D213/56 ,  C07D213/65 ,  C07D213/75 ,  C07D213/81 ,  C07D215/12 ,  C07D221/20 ,  C07D231/14 ,  C07D231/18 ,  C07D233/36 ,  C07D233/38 ,  C07D233/68 ,  C07D235/14 ,  C07D235/30 ,  C07D239/20 ,  C07D239/22 ,  C07D241/08 ,  C07D241/12 ,  C07D249/18 ,  C07D257/04 ,  C07D261/18 ,  C07D277/56 ,  C07D295/155 ,  C07D295/192 ,  C07D307/68 ,  C07D317/68 ,  C07D333/70 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/10 ,  C07D493/08 ,  C07D495/10 ,  C07D498/04 ,  C07D513/10 ,  Y02A50/30

Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.